IT / EN
Close
IT / EN
Menu

Oculopharyngeal Muscular Dystrophy (OPMD)

Oculopharyngeal Muscular Dystrophy (OPMD) is a late-onset hereditary myopathy, characterized by progressive blepharoptosis (eyelid ptosis), dysphagia, and proximal muscle weakness. The estimated prevalence is approximately 1:100,000 individuals in the Caucasian population, a figure that is likely underestimated. Onset typically occurs between the fifth and sixth decades of life. Transmission is predominantly autosomal dominant; however, rare cases of autosomal recessive transmission have been described. The disease is caused by mutations in the PABPN1 gene, consisting of an expansion of the alanine-coding sequence (from 11 up to 12–18 repeats), resulting in the formation of intranuclear protein aggregates. Progression is slow, occurring over decades, and the prognosis is generally favorable.

OPMD is a late-onset muscular dystrophy caused by the expansion of GCN triplets in exon 1 of the PABPN1 gene, located on chromosome 14q11. The normal allele contains 10 GCN repeats. Pathological expansions generally range from 12 to 17 repeats; each additional triplet leads to the insertion of a supplemental alanine into the PABPN1 protein. The mutated protein tends to aggregate, forming intranuclear inclusions that impair mRNA polyadenylation mechanisms and, ultimately, muscle fiber homeostasis.

Clinical Features and Progression of OPMD

OPMD presents a characteristic, slowly progressive clinical picture.

Onset Symptoms

  • Ptosis (≈95% of patients)

    • Bilateral, symmetrical, and slowly progressive.

    • Often the first symptom appearing between ages 40 and 50.

    • Compensatory mechanisms: eyebrow lifting (frontalis overactivity) and head tilt (extension of the neck).

    • Progressive reduction of the superior visual field.

  • Dysphagia (≈80–90% of patients)

    • Initially for solids, subsequently progressing to liquids.

    • Due to weakness of the pharyngeal muscles and the cricopharyngeal muscle.

    • Possible complications: aspiration, malnutrition, and weight loss.

    • Requirement for dietary adjustments and compensatory strategies.

Disease Progression

  • Early Phase (Ages 40–50)

    • Mild ptosis, sometimes intermittent.

    • Occasional difficulty swallowing dry foods.

    • Global muscle strength remains preserved.

  • Intermediate Phase (Ages 50–60)

    • Marked ptosis with postural compensation.

    • Dysphagia for solids; coughing during meals.

    • Possible early limitation of ocular movements.

    • Onset of proximal muscle weakness.

  • Advanced Phase (>60 years)

    • Severe ptosis with significant visual field impairment.

    • Major dysphagia with increased risk of aspiration.

    • Partial or complete ophthalmoplegia.

    • More widespread muscle weakness.

Systemic Muscle Involvement

  • Extraocular Muscles (60–80% in advanced stages)

    • Symmetrical involvement of ocular movements.

    • Diplopia (double vision) and progressive gaze limitation.

    • Possible evolution toward complete ophthalmoplegia.

  • Appendicular Musculature

    • Predominant involvement of the limb-girdle (scapular and pelvic).

    • Onset generally after age 60.

    • Slow progression, rarely associated with severe disability.

  • Laryngeal Musculature (30–50% of patients)

    • Dysphonia and hyponasal voice.

    • Potential impact on communication.

Clinical Evaluation and Diagnostic Workup

Clinical Assessment

  • Family History: Suggestive of autosomal dominant transmission.

  • Onset: After age 40.

  • Symptoms: Slowly progressive ptosis and/or dysphagia over decades.

  • Epidemiology: Origin from high-prevalence geographic areas.

Neurological Examination

  • Ptosis Measurement: MRD (Margin Reflex Distance).

  • Ocular Motility Assessment: Range of motion, limitations, and presence of diplopia.

  • Swallow Assessment: Clinical tests and pharyngeal reflex (gag reflex).

  • Muscle Strength Exam: Focus on proximal musculature.

Specific Functional Tests

  • Orthoptic Evaluation: e.g., Hess-Lancaster test.

  • Swallowing Studies: Water swallow test, videofluoroscopy (VFSS), FEES (Fiberoptic Endoscopic Evaluation of Swallowing), and esophageal manometry.

Genetic Testing (Gold Standard)

Molecular testing of the PABPN1 gene via PCR with fragment length analysis, targeting the (GCN)n repeat sequence of exon 1.

  • 10 Alanines: Normal genotype.

  • 12–18 Alanines: Pathological expansion.

  • Sensitivity: >95% in typical phenotypes.

  • Note: If negative despite high clinical suspicion, sequencing of exon 1 is indicated to search for rare point mutations.

Laboratory and Instrumental Exams

  • Laboratory Tests: Creatine Kinase (CK) levels are typically normal or mildly elevated (1–3 times the upper limit of normal). Useful for excluding other myopathies.

  • Instrumental Exams:

    • EMG (Electromyography): Myopathic pattern (short, polyphasic potentials).

    • Muscle MRI: Evidence of selective fibro-fatty replacement.

    • Muscle Biopsy (rarely required): Generally shows non-specific alterations; however, immunofluorescence for PABPN1 can identify intranuclear inclusions with high sensitivity and specificity.

Diagnostic Strategy

In cases of clinical suspicion, PABPN1 genetic testing is recommended, followed by genetic counseling.

Differential Diagnosis

  1. Myasthenia Gravis

  2. Mitochondrial Myopathies (e.g., CPEO)

  3. Myotonic Dystrophy Type 1 (DM1)

  4. Distal Oculopharyngeal Myopathy

  5. Inclusion Body Myositis (IBM)

Available therapies

Management and Therapeutic Interventions

Currently, no disease-modifying therapies are available. Management is multidisciplinary, aimed at symptom control and maintaining quality of life.

Supportive Care and Rehabilitation

  • Personalized dietary adjustments: Modifying food consistency to ensure safety during swallowing.

  • Speech and Language Therapy (SLT): Focused on swallowing rehabilitation and dysphagia management.

  • Physical Therapy: To maintain motor function and address proximal muscle weakness.

  • Regular Specialist Follow-up: Including Otolaryngology (ENT), Nutritional, and Respiratory assessments; Cardiology evaluation if indicated.

Symptomatic and Surgical Interventions

  • Ptosis Management:

    • Ptosis crutches: Special attachments for eyeglasses to support the eyelids.

    • Eyelid Surgery: Including frontalis sling or blepharoplasty for cases with significant visual field impairment.

  • Dysphagia Management:

    • Cricopharyngeal myotomy: Surgical procedure for selected cases to facilitate bolus passage through the upper esophageal sphincter.

    • PEG (Percutaneous Endoscopic Gastrostomy) placement: Indicated for severe dysphagia to ensure adequate nutrition and prevent aspiration.

Research in progress

  • Establishment of a national registry for patients with oculopharyngeal muscular dystrophy (OPMD), in collaboration with other specialized neuromuscular disease centers, aimed at future eligibility for clinical trials (currently 200–300 enrolled patients).
  • Longitudinal phenotypic characterization of the cohort.

Reference laboratory

Contacts and informations

Email: malattieneuromuscolari@policlinico.mi.it

Associazioni pazienti:

  • UILDM:  Tel. 049 8021001
  • OPMD Alliance: Organizzazione internazionale OPMD
  • Association of Oculopharyngeal Muscular Dystrophy: Risorse specifiche pazienti

Risorse specialistiche:

Genetic Testing Registry: informazioni test genetici disponibili